Molecular Partners Ag (MOLN) Current Deferred Revenue: 2020-2024
Historic Current Deferred Revenue for Molecular Partners Ag (MOLN) over the last 4 years, with Sep 2024 value amounting to -$5,001.
- Molecular Partners Ag's Current Deferred Revenue rose 11.23% to -$5,001 in Q3 2024 from the same period last year, while for Sep 2024 it was -$5,001, marking a year-over-year increase of 11.23%. This contributed to the annual value of $4.8 million for FY2023, which is 72420.37% up from last year.
- Per Molecular Partners Ag's latest filing, its Current Deferred Revenue stood at -$5,001 for Q3 2024, which was up 99.88% from -$4.1 million recorded in Q2 2024.
- In the past 5 years, Molecular Partners Ag's Current Deferred Revenue ranged from a high of $30.7 million in Q4 2021 and a low of -$9.0 million during Q2 2021.
- Its 3-year average for Current Deferred Revenue is $388,354, with a median of -$2,880 in 2023.
- As far as peak fluctuations go, Molecular Partners Ag's Current Deferred Revenue surged by 363.99% in 2022, and later crashed by 33,230.55% in 2023.
- Molecular Partners Ag's Current Deferred Revenue (Quarterly) stood at $7.7 million in 2020, then skyrocketed by 296.54% to $30.7 million in 2021, then tumbled by 78.33% to $6.7 million in 2022, then dropped by 26.57% to $4.9 million in 2023, then climbed by 11.23% to -$5,001 in 2024.
- Its last three reported values are -$5,001 in Q3 2024, -$4.1 million for Q2 2024, and -$2,781 during Q1 2024.